New transfection kit for use in cancer research shows superior transfection efficiency in prostate cells without compromising cellular health
Gene transfer specialist Mirus has developed the new Transit-Prostate transfection kit for use in cancer research.
The kit shows superior transfection efficiency in prostate cells without compromising cellular health.
As with the entire Transit range, it is efficient, simple to use, has low toxicity and high reproducibility.
High specificity makes the Transit-Prostate transfection kit a desirable alternative to broad spectrum transfection reagents for use with the prevalent cell lines in prostate cancer research.
These are often difficult to transfect using traditional methods.
The new kit is designed to achieve greater than 50% transfection efficiencies using GFP as a reporter in the common prostate cancer cell lines: DU-145, LNCaP-FGC, and PC-3.
Reagents are all supplied ready for use and can be used with serum-containing media.
The recommended method does not require media to be replaced, increasing ease and efficiency.
